Monday, April 19, 2021

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Establishes Clinical Advisory Board, to Present at Bloom Burton & Co. Health Care Investor Conference

 Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced the formation of its clinical advisory board. Additions to the board include Maurizio Fava, MD, psychiatrist-in-chief in the Department of Psychiatry at Massachusetts General Hospital, Lynn Marie Morski, MD, Esq., president of the Psychedelic Medicine Association, and Anthony Back, MD, professor in the Department of Medicine and Division of Oncology at the University of Washington. Alex Belser, PhD, Cybin’s chief clinical officer, will chair the clinical advisory board. “We are delighted to welcome three accomplished experts in their respective fields to guide the strategic development of Cybin’s clinical programs,” said Doug Drysdale, Cybin’s chief executive officer. “Together, Drs. Fava, Morski and Back add unparalleled clinical expertise and strengthen our position to advance psychedelic therapeutics. Their insights will be especially valuable as we move our development pipeline through clinical trials.”

In addition, Cybin announced that it will present at the Bloom Burton & Co. Health Care Investor Conference. According to the update, CEO Doug Drysdale is scheduled to present at 2 p.m. ET on Wednesday April 21, 2021. Interested parties should visit https://ibn.fm/VzQR7 to register for the event.

To view the full press releases, visit https://ibn.fm/JiwRK and https://ibn.fm/eGDVL

About Cybin Inc.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN  

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html